Table 3.
Study flow chart of the CDCS
| Procedures | Visit time (month) | ||||
|---|---|---|---|---|---|
| Baseline | 6 ± 1 | 12 ± 1 | 18 ± 1 | 24 ± 1 | |
| Data release consent form | ● | ||||
| Demography data | ● | ||||
| Inclusion/exclusion criteria | ● | ||||
| Physical measurements (vital signs) | ● | ||||
| Smoking and alcohol drink status | ● | ||||
| Cardiovascular risk factors | ● | ||||
| Disease history | ● | ||||
| Concomitant medications | ● | ● | ● | ● | ● |
| Hemoglobin, hematocrit | ● | ||||
| Serum total calcium, phosphorus, iPTH | ● | ● | ● | ● | ● |
| 25-OH Vit D, FGF23 | ● | ● | ● | ||
| Glucose, HDL-C, LDL-C, TC and TG | ● | ||||
| hs-CRP | ● | ||||
| Serum albumin, ferritin, alkaline phosphatase | ● | ||||
| Urea, uric acid, creatinine | ● | ||||
| ABI | ● | ||||
| Kt/V, dialysate calcium concentration | ● | ||||
| Dialysis vintage, dialysis frequency and modality, membrane type | ● | ||||
| EBCT or MDCT scan | ● | ● | |||
| Plain lateral lumbar radiograph | ● | ● | |||
| Echocardiography, LVMI/LVH | ● | ● | |||
| Clinical outcomes | ● | ● | ● | ● | |
iPTH Intact parathyroid hormone, 25-OH Vit D serum 25-hydroxyvitamin D, FGF23 Fibroblast growth factor 23, HDL-C High density lipoprotein-cholesterol, LDL-C Low density lipoprotein-cholesterol, TC Total Cholesterol, TG Triglyceride, hs-CRP High-sensitivity C-reactive protein, ABI Ankle-brachial index, EBCT Electron beam computed tomography, MDCT Multi-detector computed tomography, LVMI Left ventricular mass index, LVH Left ventricular hypertrophy